Posted on 16th May 2012 in to David Tredinnick and Parliament
David Tredinnick has welcomed today?s announcement by the National Institute for Health and Clinical Excellence (NICE) that they are to recommend abiraterone ? the breakthrough treatment for advanced prostate cancer ? on the NHS in England and Wales. NICE has now accepted the Prostate Cancer Charity?s argument that abiraterone should be treated as an ?end of life? drug and has decided to overturn its draft decision in February not to fund the drug generally on the NHS.
The Bosworth MP, who is a member of the House of Commons Health Select Committee, said, ?This is fantastic news for men with advanced prostate cancer. It means that men whose cancer has stopped responding to other hormone therapy and chemotherapy will be able to receive the drug without having to make an application through the Cancer Drugs Fund. The Prostate Cancer Charity has run a very effective campaign on this issue and I am very pleased it has been so successful.
?I wrote to the Prime Minister about this vital issue and today?s announcement represents a resounding triumph for each of the thousands of men with advanced prostate cancer. I am delighted that NICE has overturned its earlier decision after reviewing the evidence. Abiraterone is a genuine breakthrough drug that gives men with advanced prostate cancer improved quality of life.?
Bryan Jones, policy and campaigns manager for the Prostate Cancer Charity, thanked David Tredinnick saying, ?Your support for our campaign in Parliament in recent months has been vital in helping to achieve this outcome. Thank you for your work on behalf of men with prostate cancer.?
celebrity apprentice grizzlies bronx zoo crash april 30 wwe extreme rules 2012 vontaze burfict jimmy kimmel
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.